Today, Arctic Bioscience, a biotech company developing, and commercializing nutraceutical and pharmaceutical products based on the unique properties of bioactive marine compounds, host a Capital Markets Update in Oslo.
“During challenging times Arctic Bioscience has worked hard to stay on track with the development plan for HRO350, and we are now in a position to take the next steps in this development plan. We look forward to meeting with investors and other capital market stakeholders to give an update on the company and hopefully provide meaningful discussions”, says Christer L. Valderhaug, CEO at Arctic Bioscience.
Presentations will be held by Arctic Bioscience management and external experts. The presentations and the following Q&A session will be held in Norwegian. Presentation material from Arctic Bioscience attached.
The event will take place at Flyt Conference Centre, Haakon VIIs gate 2 from 10.00 – 12.00 CEST
A recording of the event will be available on the company’s web site after the event.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Christer L. Valderhaug
CEO of Arctic Bioscience AS
Mobile: +47 920 84 601
Jone R. Slinning
CFO of Arctic Bioscience AS
Mobile: +47 948 75 469
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.